Covered recipient · General Payments record
JAMES BERENSON
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$49,921.00
113 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,504.25 | 6 |
| Honoraria | $15,500.00 | 4 |
| Consulting Fee | $8,222.50 | 6 |
| Food and Beverage | $3,680.28 | 79 |
| Travel and Lodging | $1,813.99 | 16 |
| Education | $199.98 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Karyopharm Therapeutics Inc. | $17,845.71 | 25 |
| Janssen Biotech, Inc. | $15,654.67 | 26 |
| GENZYME CORPORATION | $9,912.77 | 20 |
| PFIZER INC. | $2,333.60 | 10 |
| Aadi Bioscience, Inc. | $1,700.00 | 2 |
| Merck Sharp & Dohme LLC | $1,250.00 | 2 |
| GlaxoSmithKline, LLC. | $308.13 | 8 |
| SANOFI-AVENTIS U.S. LLC | $166.79 | 2 |
| Janssen Scientific Affairs, LLC | $147.56 | 2 |
| Regeneron Healthcare Solutions, Inc. | $145.63 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $138.69 | 4 |
| Sebia Inc | $123.71 | 1 |
| Legend Biotech USA Inc. | $89.97 | 3 |
| AstraZeneca Pharmaceuticals LP | $29.45 | 1 |
| Sumitomo Pharma America, Inc. | $27.78 | 1 |
| Incyte Corporation | $26.98 | 1 |
| Celgene Corporation | $19.56 | 1 |
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES BERENSON
NPI 1124051560 · CMS profile ID 277183
WEST HOLLYWOOD, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124051560?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES BERENSON, NPI 1124051560, CMS profile ID 277183. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124051560?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JAMES BERENSON, NPI 1124051560, CMS profile ID 277183. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124051560?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JAMES BERENSON, NPI 1124051560, CMS profile ID 277183, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124051560?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
113 matching records · $49,921.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–113 of 113.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $28.06 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174879010 | CMS |
| Karyopharm Therapeutics Inc. | $31.22 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246646281 | CMS |
| Janssen Biotech, Inc. | $2.87 | 02/26/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174880197 | CMS |
| Karyopharm Therapeutics Inc. | $21.39 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246646277 | CMS |
| Janssen Biotech, Inc. | $3,607.50 | 02/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174879305 | CMS |
| Janssen Biotech, Inc. | $120.85 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174878709 | CMS |
| PFIZER INC. | $23.13 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230315843 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $31.43 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223926325 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.45 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215318295 | CMS |
| Janssen Biotech, Inc. | $26.85 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174880280 | CMS |
| Janssen Biotech, Inc. | $23.67 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174878629 | CMS |
| GlaxoSmithKline, LLC. | $20.30 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191572050 | CMS |
| Karyopharm Therapeutics Inc. | $22.48 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246646274 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $41,609.00 | 2 |
| PY2025 | Principal investigator | $1,172,651.09 | 21 |
| PY2024 | Principal investigator | $1,112,029.84 | 40 |
| PY2023 | Recipient | $81,660.00 | 2 |
| PY2023 | Principal investigator | $804,710.23 | 53 |
| PY2022 | Principal investigator | $1,364,845.78 | 39 |
| PY2021 | Principal investigator | $928,901.50 | 26 |
| PY2020 | Principal investigator | $855,132.84 | 34 |
| PY2019 | Recipient | $980.52 | 2 |
| PY2019 | Principal investigator | $1,115,512.75 | 32 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
23 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $34,796.72 | 11/04/2025 | Non-covered Recipient Entity Berenson Cancer Center | A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14) | No dispute reported | 06/30/2026 | 1226120620 |
| Principal investigator 1 | ABBVIE INC. | $6,575.00 | 08/28/2025 | Non-covered Recipient Entity JAMES R BERENSON MD INC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202506327 |
| Principal investigator 1 | ABBVIE INC. | $93,708.00 | 08/20/2025 | Non-covered Recipient Entity BERENSON CANCER CENTER | A phase 1 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma (RRMM) patients | No dispute reported | 06/30/2026 | 1202505309 |
| Principal investigator 1 | GENZYME CORPORATION | $108,739.75 | 08/15/2025 | Non-covered Recipient Entity Berenson Cancer Center | Not supplied | No dispute reported | 06/30/2026 | 1226120613 |
| Principal investigator 1 | GENZYME CORPORATION | $10,438.92 | 08/15/2025 | Non-covered Recipient Entity Berenson Cancer Center | Not supplied | No dispute reported | 06/30/2026 | 1226120617 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $65,962.15 | 08/15/2025 | Non-covered Recipient Entity Oncotherapeutics | A phase 1 trial of selinexor, ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma | No dispute reported | 06/30/2026 | 1246664330 |
| Recipient | GENZYME CORPORATION | $19,287.00 | 07/02/2025 | Covered Recipient Physician | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226083002 |
| Principal investigator 1 | GENZYME CORPORATION | $5,057.64 | 06/12/2025 | Non-covered Recipient Entity Berenson Cancer Center | A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14) | No dispute reported | 06/30/2026 | 1226120605 |
| Principal investigator 1 | GENZYME CORPORATION | $25,288.32 | 06/12/2025 | Non-covered Recipient Entity Berenson Cancer Center | A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14) | No dispute reported | 06/30/2026 | 1226120608 |
| Principal investigator 1 | ABBVIE INC. | $21,050.00 | 05/07/2025 | Non-covered Recipient Entity JAMES R BERENSON MD INC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202483957 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 04/28/2025 | Non-covered Recipient Entity Berenson James R MD | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175182249 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $68,875.00 | 04/17/2025 | Non-covered Recipient Entity James R Berenson Md Incorporated | Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients. | No dispute reported | 06/30/2026 | 1235996503 |
| Principal investigator 1 | GENZYME CORPORATION | $143,858.57 | 04/07/2025 | Non-covered Recipient Entity Oncotherapeutics | A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14) | No dispute reported | 06/30/2026 | 1226093288 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $10,983.00 | 03/17/2025 | Non-covered Recipient Entity James R Berenson MD, Inc. | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246663597 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,262.60 | 03/13/2025 | Non-covered Recipient Entity James R Berenson Md Incorporated | Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab | No dispute reported | 06/30/2026 | 1235996501 |
| Principal investigator 1 | Incyte Corporation | $19,545.00 | 02/18/2025 | Non-covered Recipient Entity Oncotherapeutics | Treatment of R/R MM Pts with ruxolitinib and Methylprednisolone: Using Changes in Serum BCell Maturation Antigen (BCMA) or International Multiple Working Group (IMWG) Criteria to Determine Progression in order to add Lenalidomide | No dispute reported | 06/30/2026 | 1240571374 |
| Principal investigator 1 | ABBVIE INC. | $531,012.00 | 02/10/2025 | Non-covered Recipient Entity BERENSON CANCER CENTER | A21-895;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets | No dispute reported | 06/30/2026 | 1202450475 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $22,322.00 | 02/07/2025 | Covered Recipient Physician | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF TAK-573 AS A SINGLE AGENT IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1223262696 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 01/30/2025 | Non-covered Recipient Entity James R Berenson MD Inc. | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175167388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 01/30/2025 | Non-covered Recipient Entity James R Berenson MD Inc. | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175167416 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 01/30/2025 | Non-covered Recipient Entity James R Berenson MD Inc. | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175167495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,100.00 | 01/30/2025 | Non-covered Recipient Entity James R Berenson MD Inc. | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175182233 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $3,398.42 | 01/24/2025 | Non-covered Recipient Entity Mayo Clinic | Phase Ib trial of Low-Dose Selinexor (KPT-330) in combination with Choline Salicylate (CS) for the treatment of patients with residual/relapsed/refractory non-Hodgkin lymphoma (NHL) | No dispute reported | 06/30/2026 | 1246663928 |